Testing two combination medications for advanced lung cancer with EGFR mutations

Plain-English translation of NCT06668103 on ClinicalTrials.gov ↗ · Source last updated December 2024 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing whether ABSK043 and firmonertinib work better together to treat advanced non-small cell lung cancer that has specific EGFR mutations. You would take both medications by mouth, and researchers would carefully monitor your safety and how well the treatment works. This is an early-stage trial designed to find the right dose and confirm that this combination is effective.

Some lung cancers have EGFR mutations that make them grow faster, and while there are treatments available, doctors want to find better combinations that work more effectively and help patients live longer.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic non-small cell lung cancer with an EGFR mutation (specifically an exon 19 deletion or L858R mutation)
you have at least one measurable tumor that can be seen on imaging scans
your tumor shows a positive PDL1 expression test from a tissue sample
you have adequate organ function based on recent blood tests
for the dose-escalation part: you have already received at least one prior EGFR-targeted treatment and your cancer has progressed; for the expansion part: you have not yet received any systemic chemotherapy for advanced disease

You likely don't qualify if…

you have a history of interstitial lung disease or active pneumonitis
you have brain metastases that are causing symptoms or requiring steroids or anti-seizure medications
you are currently taking high-dose corticosteroids (more than 10 mg prednisone daily) or other immunosuppressive medications
you have uncontrolled heart disease or significant cardiovascular problems
you have unresolved side effects from previous cancer treatments that haven't improved to mild or absent

What participation looks like

You would take both medications by mouth according to a specific schedule determined by the study. The trial has two phases: first, researchers test different doses with previously treated patients to find the safest and most effective combination; then, they give that dose to newly diagnosed patients who have never received systemic chemotherapy. Throughout the study, you'll have regular clinic visits for blood tests, imaging scans to measure your tumors, and check-ins about any side effects you're experiencing.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

Trial locations(5 sites)

China

Hanhui Cancer Hospital, Hefei, Anhui

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Union Hospital Tongji Medical College Huzhong University of Science and Techology, Wuhan, Hubei

Jilin Cancer Hospital, Changchun, Jilin

Shanghai Chest Hospital, Shanghai, Shanghai Municipality